InvestorsHub Logo
Followers 188
Posts 29010
Boards Moderated 1
Alias Born 08/29/2012

Re: dr_lowenstein post# 71752

Monday, 09/30/2013 8:00:12 PM

Monday, September 30, 2013 8:00:12 PM

Post# of 403496
Elite's first agonist/antagonist ELI216 to be submitted for 505b2 approval is expected to be oxycodone/naltrexone as ELI216-OXY/NAL. The FDA submittal is expected by mid-2014 or sooner following 38 persons studies starting Nov/Dec 2013.
btfd
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News